Prognostic models and autoimmune liver diseases.

Area of Science:

• Hepatology
• Immunology
• Rare Diseases

Background:

• Autoimmune liver diseases (AILDs) like PBC, PSC, and AIH are immune-mediated with unknown causes.
• While treatments exist for PBC and AIH, PSC lacks medical therapy beyond liver transplantation (LT).
• These rare diseases collectively represent a significant portion (20%) of LTs in Europe and the USA, posing management challenges due to heterogeneity.

Purpose of the Study:

• To review the challenges in managing AILDs.
• To discuss the role of prognostic models in personalized patient care for AILDs.
• To highlight specific prognostic models for PBC, PSC, and AIH.

Main Methods:

• Review of existing literature on AILDs and prognostic models.
• Focus on models supporting clinical management in PBC, PSC, and AIH.
• Analysis of biomarkers including biochemical, serological, histological, and radiological markers.

Main Results:

• Prognostic models for PBC utilize ursodeoxycholic acid (UDCA) response and fibrosis markers.
• PSC management can be supported by biochemical markers, disease stage, and radiological assessments.
• AIH prognostic models incorporate disease stage and activity markers.

Conclusions:

• Prognostic models are crucial for assessing risk and personalizing care in AILDs.
• Available models offer valuable tools for clinicians managing PBC, PSC, and AIH.
• Further development and application of these models can improve patient outcomes in autoimmune liver diseases.